Is ACTU or BFRG more profitable?

Bullfrog AI's return on equity of -217.80% beat Actuate Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Actuate Therapeutics N/A -430.93% -180.86% Bullfrog AI N/A -217.80% -174.57%

Do analysts rate MGX or BFRG?

Metagenomi presently has a consensus price target of $9.00, indicating a potential upside of 634.69%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts clearly believe Metagenomi is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Metagenomi 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80 Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is MGX or BFRG more profitable?

Bullfrog AI has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Metagenomi -384.61% -51.23% -36.62% Bullfrog AI N/A -217.80% -174.57%

Do analysts rate ATHE or BFRG?

Alterity Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 104.62%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ATHE or BFRG?

Bullfrog AI has higher revenue and earnings than Alterity Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Bullfrog AI $116.67K 105.37 -$6.50M -$0.54 N/A

Is ATHE or BFRG more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Alterity Therapeutics N/A N/A N/A Bullfrog AI N/A -217.80% -174.57%

Do analysts rate BFRG or NBRV?

Given Nabriva Therapeutics' higher possible upside, analysts clearly believe Nabriva Therapeutics is more favorable than Bullfrog AI. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nabriva Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts rate APLM or BFRG?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Bullfrog AI 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger valuation and earnings, APLM or BFRG?

Bullfrog AI has lower revenue, but higher earnings than Apollomics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Apollomics $8.50M 5.21 -$10.94M N/A N/A Bullfrog AI $116.67K 105.37 -$6.50M -$0.54 N/A

Is APLM or BFRG more profitable?

Apollomics' return on equity of 0.00% beat Bullfrog AI's return on equity. Company Net Margins Return on Equity Return on Assets Apollomics N/A N/A N/A Bullfrog AI N/A -217.80% -174.57%

Does the media refer more to APLM or BFRG?

In the previous week, Apollomics had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.87 beat Apollomics' score of 0.64 indicating that Bullfrog AI is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apollomics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Bullfrog AI 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Bullfrog AI (BFRG) Competitors

$0.65 +0.04 (+6.38%)

As of 03:58 PM Eastern

Compare

BFRG vs. ACTU, MGX, ATHE, NBRV, and APLM

Should you buy Bullfrog AI stock or one of its competitors? MarketBeat compares Bullfrog AI with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Bullfrog AI include Actuate Therapeutics (ACTU), Metagenomi (MGX), Alterity Therapeutics (ATHE), Nabriva Therapeutics (NBRV), and Apollomics (APLM). These companies are all part of the "pharmaceutical products" industry.

How does Bullfrog AI compare to Actuate Therapeutics?

Actuate Therapeutics (NASDAQ:ACTU) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, dividends, institutional ownership, profitability, media sentiment and earnings.

In the previous week, Bullfrog AI had 1 more articles in the media than Actuate Therapeutics. MarketBeat recorded 2 mentions for Bullfrog AI and 1 mentions for Actuate Therapeutics. Actuate Therapeutics' average media sentiment score of 1.89 beat Bullfrog AI's score of 0.87 indicating that Actuate Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Actuate Therapeutics	Very Positive
Bullfrog AI	Positive

Actuate Therapeutics presently has a consensus target price of $17.50, indicating a potential upside of 865.25%. Given Actuate Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Actuate Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Actuate Therapeutics	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

1.0% of Bullfrog AI shares are owned by institutional investors. 58.0% of Actuate Therapeutics shares are owned by company insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Bullfrog AI has higher revenue and earnings than Actuate Therapeutics. Actuate Therapeutics is trading at a lower price-to-earnings ratio than Bullfrog AI, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Actuate Therapeutics	N/A	N/A	-$22.23M	-$0.97	N/A
Bullfrog AI	$116.67K	105.37	-$6.50M	-$0.54	N/A

Actuate Therapeutics has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.89, suggesting that its share price is 389% less volatile than the broader market.

Bullfrog AI's return on equity of -217.80% beat Actuate Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Actuate Therapeutics	N/A	-430.93%	-180.86%
Bullfrog AI	N/A	-217.80%	-174.57%

Summary

Bullfrog AI beats Actuate Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Bullfrog AI compare to Metagenomi?

Metagenomi (NASDAQ:MGX) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

In the previous week, Bullfrog AI had 1 more articles in the media than Metagenomi. MarketBeat recorded 2 mentions for Bullfrog AI and 1 mentions for Metagenomi. Metagenomi's average media sentiment score of 1.89 beat Bullfrog AI's score of 0.87 indicating that Metagenomi is being referred to more favorably in the media.

Company	Overall Sentiment
Metagenomi	Very Positive
Bullfrog AI	Positive

Bullfrog AI has lower revenue, but higher earnings than Metagenomi. Bullfrog AI is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Metagenomi	$25.21M	1.83	-$87.87M	-$2.30	N/A
Bullfrog AI	$116.67K	105.37	-$6.50M	-$0.54	N/A

1.0% of Bullfrog AI shares are owned by institutional investors. 12.5% of Metagenomi shares are owned by company insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Metagenomi has a beta of 0.64, indicating that its stock price is 36% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.89, indicating that its stock price is 389% less volatile than the broader market.

Metagenomi presently has a consensus price target of $9.00, indicating a potential upside of 634.69%. Given Metagenomi's stronger consensus rating and higher probable upside, research analysts clearly believe Metagenomi is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Metagenomi	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has a net margin of 0.00% compared to Metagenomi's net margin of -384.61%. Metagenomi's return on equity of -51.23% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Metagenomi	-384.61%	-51.23%	-36.62%
Bullfrog AI	N/A	-217.80%	-174.57%

Summary

Metagenomi beats Bullfrog AI on 10 of the 17 factors compared between the two stocks.

How does Bullfrog AI compare to Alterity Therapeutics?

Alterity Therapeutics (NASDAQ:ATHE) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, dividends, risk, profitability, media sentiment and valuation.

Alterity Therapeutics' return on equity of 0.00% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Bullfrog AI	N/A	-217.80%	-174.57%

In the previous week, Alterity Therapeutics and Alterity Therapeutics both had 2 articles in the media. Alterity Therapeutics' average media sentiment score of 0.96 beat Bullfrog AI's score of 0.87 indicating that Alterity Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Alterity Therapeutics	Positive
Bullfrog AI	Positive

Alterity Therapeutics currently has a consensus target price of $10.00, indicating a potential upside of 104.62%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Bullfrog AI has higher revenue and earnings than Alterity Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Bullfrog AI	$116.67K	105.37	-$6.50M	-$0.54	N/A

Alterity Therapeutics has a beta of 0.3, indicating that its share price is 70% less volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.89, indicating that its share price is 389% less volatile than the broader market.

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Alterity Therapeutics beats Bullfrog AI on 9 of the 11 factors compared between the two stocks.

How does Bullfrog AI compare to Nabriva Therapeutics?

Bullfrog AI (NASDAQ:BFRG) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, profitability, media sentiment, valuation, institutional ownership, analyst recommendations, risk and dividends.

Bullfrog AI has a beta of -2.89, suggesting that its stock price is 389% less volatile than the broader market. Comparatively, Nabriva Therapeutics has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

1.0% of Bullfrog AI shares are owned by institutional investors. Comparatively, 0.3% of Nabriva Therapeutics shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by company insiders. Comparatively, 1.6% of Nabriva Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bullfrog AI has a net margin of 0.00% compared to Nabriva Therapeutics' net margin of -148.11%. Bullfrog AI's return on equity of -217.80% beat Nabriva Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bullfrog AI	N/A	-217.80%	-174.57%
Nabriva Therapeutics	-148.11%	-365.53%	-135.81%

In the previous week, Bullfrog AI had 2 more articles in the media than Nabriva Therapeutics. MarketBeat recorded 2 mentions for Bullfrog AI and 0 mentions for Nabriva Therapeutics. Bullfrog AI's average media sentiment score of 0.87 beat Nabriva Therapeutics' score of 0.00 indicating that Bullfrog AI is being referred to more favorably in the media.

Company	Overall Sentiment
Bullfrog AI	Positive
Nabriva Therapeutics	Neutral

Given Nabriva Therapeutics' higher possible upside, analysts clearly believe Nabriva Therapeutics is more favorable than Bullfrog AI.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nabriva Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Bullfrog AI has higher earnings, but lower revenue than Nabriva Therapeutics. Bullfrog AI is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bullfrog AI	$116.67K	105.37	-$6.50M	-$0.54	N/A
Nabriva Therapeutics	$35.59M	0.00	-$57.19M	-$19.20	N/A

Summary

Bullfrog AI beats Nabriva Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Bullfrog AI compare to Apollomics?

Apollomics (NASDAQ:APLM) and Bullfrog AI (NASDAQ:BFRG) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, media sentiment, analyst recommendations, profitability, risk and dividends.

In the previous week, Apollomics had 1 more articles in the media than Bullfrog AI. MarketBeat recorded 3 mentions for Apollomics and 2 mentions for Bullfrog AI. Bullfrog AI's average media sentiment score of 0.87 beat Apollomics' score of 0.64 indicating that Bullfrog AI is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apollomics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Bullfrog AI	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Apollomics has a beta of 1.53, meaning that its stock price is 53% more volatile than the broader market. Comparatively, Bullfrog AI has a beta of -2.89, meaning that its stock price is 389% less volatile than the broader market.

Bullfrog AI has lower revenue, but higher earnings than Apollomics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apollomics	$8.50M	5.21	-$10.94M	N/A	N/A
Bullfrog AI	$116.67K	105.37	-$6.50M	-$0.54	N/A

19.1% of Apollomics shares are owned by institutional investors. Comparatively, 1.0% of Bullfrog AI shares are owned by institutional investors. 14.7% of Bullfrog AI shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apollomics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Bullfrog AI	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Apollomics' return on equity of 0.00% beat Bullfrog AI's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apollomics	N/A	N/A	N/A
Bullfrog AI	N/A	-217.80%	-174.57%

Summary

Apollomics beats Bullfrog AI on 6 of the 10 factors compared between the two stocks.

Get Bullfrog AI News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BFRG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BFRG vs. The Competition

Export

Metric	Bullfrog AI	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$12.29M	$1.68B	$6.78B	$12.18B
Dividend Yield	N/A	N/A	2.68%	5.90%
P/E Ratio	-1.23	78.68	25.66	24.03
Price / Sales	105.37	7.07	554.87	99.66
Price / Cash	N/A	23.94	46.33	53.91
Price / Book	3.49	5.48	10.69	6.31
Net Income	-$6.50M	-$54.76M	$3.57B	$337.69M
7 Day Performance	-8.25%	-1.35%	2.30%	-0.94%
1 Month Performance	-6.34%	-1.21%	1.47%	-0.31%
1 Year Performance	-57.77%	-0.53%	31.70%	25.81%

Bullfrog AI Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BFRG Bullfrog AI	0.9149 of 5 stars	$0.65 +6.4%	N/A	-62.0%	$12.13M	$116.67K	N/A	4
ACTU Actuate Therapeutics	2.8018 of 5 stars	$2.01 +3.9%	$17.50 +772.8%	-69.6%	$47.97M	N/A	N/A	10	Analyst Forecast Gap Up
MGX Metagenomi	3.4969 of 5 stars	$1.26 +1.6%	$9.00 +614.3%	-23.7%	$47.44M	$25.21M	N/A	236	Analyst Downgrade
ATHE Alterity Therapeutics	2.6954 of 5 stars	$5.16 +4.0%	$10.00 +93.8%	+27.6%	$45.75M	N/A	N/A	10	Short Interest Increase High Trading Volume
NBRV Nabriva Therapeutics	N/A	N/A	N/A	N/A	$45.46M	$35.59M	N/A	70	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BFRG) was last updated on 6/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bullfrog AI (BFRG) Competitors

BFRG vs. ACTU, MGX, ATHE, NBRV, and APLM

How does Bullfrog AI compare to Actuate Therapeutics?

Summary

How does Bullfrog AI compare to Metagenomi?

Summary

How does Bullfrog AI compare to Alterity Therapeutics?

Summary

How does Bullfrog AI compare to Nabriva Therapeutics?

Summary

How does Bullfrog AI compare to Apollomics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG vs. The Competition

Bullfrog AI Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bullfrog AI (BFRG) Competitors

BFRG vs. ACTU, MGX, ATHE, NBRV, and APLM

How does Bullfrog AI compare to Actuate Therapeutics?

Does the media refer more to ACTU or BFRG?

Do analysts recommend ACTU or BFRG?

Do institutionals & insiders believe in ACTU or BFRG?

Which has stronger valuation & earnings, ACTU or BFRG?

Which has more risk and volatility, ACTU or BFRG?

Is ACTU or BFRG more profitable?

Summary

How does Bullfrog AI compare to Metagenomi?

Does the media refer more to MGX or BFRG?

Which has better valuation & earnings, MGX or BFRG?

Do insiders and institutionals believe in MGX or BFRG?

Which has more risk and volatility, MGX or BFRG?

Do analysts rate MGX or BFRG?

Is MGX or BFRG more profitable?

Summary

How does Bullfrog AI compare to Alterity Therapeutics?

Is ATHE or BFRG more profitable?

Does the media refer more to ATHE or BFRG?

Do analysts rate ATHE or BFRG?

Which has higher earnings and valuation, ATHE or BFRG?

Which has more risk & volatility, ATHE or BFRG?

Do insiders & institutionals believe in ATHE or BFRG?

Summary

How does Bullfrog AI compare to Nabriva Therapeutics?

Which has more risk and volatility, BFRG or NBRV?

Do institutionals and insiders hold more shares of BFRG or NBRV?

Is BFRG or NBRV more profitable?

Does the media favor BFRG or NBRV?

Do analysts rate BFRG or NBRV?

Which has higher earnings and valuation, BFRG or NBRV?

Summary

How does Bullfrog AI compare to Apollomics?

Does the media refer more to APLM or BFRG?

Which has more volatility & risk, APLM or BFRG?

Which has stronger valuation and earnings, APLM or BFRG?

Do institutionals and insiders have more ownership in APLM or BFRG?

Do analysts rate APLM or BFRG?

Is APLM or BFRG more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BFRG vs. The Competition

Bullfrog AI Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools